Updated Phase 2 Survival Data of Cyclacel Pharmaceuticals, Inc.'s Sapacitabine for MDS Presented at the Eighth Annual Hematologic Malignancies 2012 Conference
Published: Oct 12, 2012
BERKELEY HEIGHTS, N.J., Oct. 12, 2012 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company) announced that updated data from an ongoing, multicenter, Phase 2 randomized trial of oral sapacitabine capsules, the Company's lead product candidate, in older patients with intermediate-2 or high-risk myelodysplastic syndromes (MDS) after treatment failure of front-line hypomethylating agents, such as azacitidine (Vidaza®) and/or decitabine (Dacogen®), will be discussed at two separate sessions at The Eighth Annual Hematologic Malignancies 2012 Conference being held on October 10-14, 2012, in Houston, Texas. Median overall survival to date for all 63 patients is 252 days or approximately 8 months. Median overall survival for 41 out of 63 patients with 10% or more blasts in their bone marrow is 274 days or approximately 9 months.